Fred Stephen Sarfo1,2, Bruce Ovbiagele3. 1. Department of Medicine, Kwame Nkrumah University of Science & Technology, Private Mail Bag, Kumasi, Ghana. stephensarfo78@gmail.com. 2. Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana. stephensarfo78@gmail.com. 3. Department of Neurology, University of California, San Francisco, USA.
Abstract
PURPOSE OF REVIEW: Worldwide, compared to other racial/ethnic groups, individuals of African ancestry have an excessively higher burden of hypertension-related morbidities, especially stroke. Identifying modifiable biological targets that contribute to these disparities could improve global stroke outcomes. In this scoping review, we discuss how pathological perturbations in the renin-angiotensin-aldosterone pathways could be harnessed via physiological profiling for the purposes of improving blood pressure control for stroke prevention among people of African ancestry. RECENT FINDINGS: Transcontinental comparative data from the USA and Ghana show that the prevalence of treatment-resistant hypertension among stroke survivors is 42.7% among indigenous Africans, 16.1% among African Americans, and 6.9% among non-Hispanic Whites, p < 0.0001. A multicenter clinical trial of patients without stroke in 3 African countries (Nigeria, Kenya, and South Africa) demonstrated that physiological profiling using plasma renin activity and aldosterone to individualize selection of antihypertensive medications compared with usual care resulted in better blood pressure control with fewer medications over 12 months. Among Ghanaian ischemic stroke survivors treated without renin-aldosterone profiling data, an analysis revealed that those with low renin phenotypes did not achieve any meaningful reduction in blood pressure over 12 months on 3-4 antihypertensive medications despite excellent adherence. For a polygenic condition such as hypertension, individualized therapy based on plasma renin-aldosterone-guided selection of therapy for uncontrolled BP following precision medicine principles may be a viable strategy for primary and secondary stroke prevention with the potential to reduce disparities in the poor outcomes of stroke disproportionately shared by individuals of African ancestry. A dedicated clinical trial to test this hypothesis is warranted.
PURPOSE OF REVIEW: Worldwide, compared to other racial/ethnic groups, individuals of African ancestry have an excessively higher burden of hypertension-related morbidities, especially stroke. Identifying modifiable biological targets that contribute to these disparities could improve global stroke outcomes. In this scoping review, we discuss how pathological perturbations in the renin-angiotensin-aldosterone pathways could be harnessed via physiological profiling for the purposes of improving blood pressure control for stroke prevention among people of African ancestry. RECENT FINDINGS: Transcontinental comparative data from the USA and Ghana show that the prevalence of treatment-resistant hypertension among stroke survivors is 42.7% among indigenous Africans, 16.1% among African Americans, and 6.9% among non-Hispanic Whites, p < 0.0001. A multicenter clinical trial of patients without stroke in 3 African countries (Nigeria, Kenya, and South Africa) demonstrated that physiological profiling using plasma renin activity and aldosterone to individualize selection of antihypertensive medications compared with usual care resulted in better blood pressure control with fewer medications over 12 months. Among Ghanaian ischemic stroke survivors treated without renin-aldosterone profiling data, an analysis revealed that those with low renin phenotypes did not achieve any meaningful reduction in blood pressure over 12 months on 3-4 antihypertensive medications despite excellent adherence. For a polygenic condition such as hypertension, individualized therapy based on plasma renin-aldosterone-guided selection of therapy for uncontrolled BP following precision medicine principles may be a viable strategy for primary and secondary stroke prevention with the potential to reduce disparities in the poor outcomes of stroke disproportionately shared by individuals of African ancestry. A dedicated clinical trial to test this hypothesis is warranted.
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2013-12-18 Impact factor: 29.690
Authors: Fred S Sarfo; John Akassi; Dominic Awuah; Sheila Adamu; Clara Nkyi; Mayowa Owolabi; Bruce Ovbiagele Journal: J Neurol Sci Date: 2015-08-04 Impact factor: 3.181
Authors: W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar Journal: Stroke Date: 1999-04 Impact factor: 7.914
Authors: Virginia J Howard; Dawn O Kleindorfer; Suzanne E Judd; Leslie A McClure; Monika M Safford; J David Rhodes; Mary Cushman; Claudia S Moy; Elsayed Z Soliman; Brett M Kissela; George Howard Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: Richard Walker; David Whiting; Nigel Unwin; Ferdinand Mugusi; Mark Swai; Eric Aris; Ahmed Jusabani; Gregory Kabadi; William K Gray; Mary Lewanga; George Alberti Journal: Lancet Neurol Date: 2010-07-06 Impact factor: 44.182
Authors: Brett Kissela; Alexander Schneider; Dawn Kleindorfer; Jane Khoury; Rosemary Miller; Kathleen Alwell; Daniel Woo; Jerzy Szaflarski; James Gebel; Charles Moomaw; Arthur Pancioli; Edward Jauch; Rakesh Shukla; Joseph Broderick Journal: Stroke Date: 2004-02 Impact factor: 7.914
Authors: Bruce Ovbiagele; Larry B Goldstein; Randall T Higashida; Virginia J Howard; S Claiborne Johnston; Olga A Khavjou; Daniel T Lackland; Judith H Lichtman; Stephanie Mohl; Ralph L Sacco; Jeffrey L Saver; Justin G Trogdon Journal: Stroke Date: 2013-05-22 Impact factor: 7.914
Authors: Fred Stephen Sarfo; Dominic Otto Awuah; Clara Nkyi; John Akassi; Ohene K Opare-Sem; Bruce Ovbiagele Journal: J Neurol Sci Date: 2016-02-17 Impact factor: 3.181